Regeneron Pharmaceuticals, Inc. (REGN)

Why Is Regeneron (REGN) Up 14% Since Last Earnings Report?

China Negotiates Bargain Prices With Big Pharma

Alnylam Gets Second Product Approval Amid Stiff Competition

Esperion's Promising Drugs Under Review, Funds a Concern

New England Journal of Medicine Publishes Results of Ebola Clinical Trial Confirming Superiority of Regeneron's REGN-EB3 to ZMapp in Preventing Ebola Deaths